期刊
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
卷 5, 期 1, 页码 228-230出版社
WILEY
DOI: 10.1016/j.trci.2019.05.003
关键词
Financial conflicts of interest; Dementia; Clinical practice guidelines; Japan; Pharmaceutical payments
资金
- Ain Pharmacies
- Waseda Chronicle
IntroductionFinancial relationships between pharmaceutical companies and dementia clinical practice guideline (CPG) authors are possibly biasing the recommendations in Japan. This study aimed to reveal characteristics and distribution of pharmaceutical payments made to Japanese dementia CPG authors and an extent of the transparency in the conflicts of interest disclosure among them. MethodsWe retrospectively retrieved the publicly available data on payment to all the authors in the dementia CPGs by major pharmaceutical companies in Japan in2016. ResultsThe total and mean payment values from pharmaceutical companies were $880,061 and $14,427, respectively. Of the 61 authors, 49 (80.3%) physicians received at least one payment. Financial relationships of the individual authors were not disclosed in the CPGs. DiscussionPharmaceutical companies with antidementia drugs had strong financial relationships with the CPG authors. To guarantee fairness in their relationships, it is imperative to establish a framework to disclose the corporate financial conflicts of interest.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据